Skip to main content
¿Necesita servicios de traducción?
Comuníquese con nuestra mesa de ayuda 24/7/365 al 877-635-9545.
Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office Young businesswoman using a digital tablet while standing in front of windows in office

ProAct
Resources

 

First Generic of Symbicort Launched

First Generic of Symbicort Launched hero image

On July 31, 2023, Viatris and Kindeva launched Breyna™, an AB-rated generic version of AstraZeneca’s Symbicort® (budesonide/formoterol) metered-dose inhaler. This generic medication was approved by the FDA on March 15, 2022 and is used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Breyna’s™ wholesale acquisition cost (WAC) is approximately a 39% discount off Symbicort®. ProAct will work with our members taking Symbicort® to transition from the brand name medication to the lower cost generic alternative. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-symbicort-treat-asthma-and-copd

Manage Costs and Reduce Waste with ProAct's Wipe Out Waste Program

Manage Costs and Reduce Waste with ProAct's Wipe Out Waste Program hero image

ProAct understands that managing costs and driving out waste are critical concerns for plan sponsors. Our Wipe Out Waste (WOW) Program detects high-cost/low-value products and generates a list of wasteful items that you, as a plan sponsor, may choose to exclude from your pharmacy benefit. Wasteful products may include high-cost unique dosage forms, new non-FDA approved drugs, high-cost topical pain management therapies not aligned to FDA-approved prescribing guidance, unnecessarily combined products often marketed in a higher cost package or kit, or select 510K products (medical devices that do not alter body chemistry and that follow an approval process separate from standard FDA-approved drugs).

FDA Approves the First Over-the-Counter Oral Contraceptive

FDA Approves the First Over-the-Counter Oral Contraceptive hero image

On July 13, 2023, the Food and Drug Administration (FDA) approved the first oral contraceptive available over-the-counter (OTC) to prevent pregnancy without age restrictions. Opill (norgestrel 0.075 mg tablets), a progestin-only contraceptive, is the first daily, oral contraceptive approved in the United States for use without a prescription. Opill's OTC approval will allow for consumer purchase at a variety of retail outlets, including drug stores, grocery stores, convenience stores, and online. Opill will be available in stores and online in the first quarter of 2024. Pricing information for Opill has not yet been released.

For more information, visit: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/opill-0075mg-oral-norgestrel-tablet-information

Inflation Reduction Act & Drug Price Negotiation Program Update

Inflation Reduction Act & Drug Price Negotiation Program Update hero image

The Inflation Reduction Act (IRA) of 2022 established a Drug Price Negotiation (DPN) Program for Medicare. The program requires the U.S. Department of Health and Human Services (HHS) to negotiate prices with drug manufacturers for some single-source medications covered under Medicare Part B and Part D. HHS is scheduled to release, on September 1, 2023, the first list of selected, qualifying medications, and to begin negotiations on October 1, 2023. In June 2023, Merck & Co. filed the first lawsuit against HHS challenging the constitutionality of the DPN program. The Ohio Chamber of Commerce, Bristol Myers Squibb, and Pharmaceutical Research and Manufacturers of America have also filed lawsuits challenging the constitutionality of the DPN program. The impact the DPN program will have in the commercial space is still unknown as prices on the selected single-source medications could remained unchanged or even possibly increase as drug manufacturers look to offset losses in revenue. For more information, visit: https://www.cms.gov/inflation-reduction-act-and-medicare/medicare-drug-price-negotiation and https://jamanetwork.com/journals/jama-health-forum/fullarticle/2787467

Humira Biosimilar Formulary Update

Humira Biosimilar Formulary Update hero image

Inflammatory medications represented nearly 30% of total drug spend across our book of business in 2022.  It’s estimated that competition created with biosimilars can save the U.S. $225 billion to $375 billion in pharmacy spend by 2031.

As part of our commitment to driving greater affordability, ProAct will add the following biosimilar products to our Advantage and Core formularies, alongside Humira (adalimumab) and the biosimilar Amjevita (adalimumab-atto):

  • Cyltezo (adalimumab-adbm) (Boehringer Ingelheim), the first interchangeable biosimilar with Humira, low concentration formulation
  • Adalimumab-adaz (Sandoz), high-concentration formulation, unbranded
  • Hyrimoz (Sandoz), high-concentration formulation

ProAct will continue to conduct individual reviews of new biosimilar products for potential formulary placement as they become available, to ensure each product meets clinical standards and provides cost-savings. We are also committed to helping accelerate the market transition to biosimilars while preserving choice and flexibility for patients.

ProAct Logo ProAct Logo ProAct Logo
mobile image tablet image desktop image